{"id":"https://openalex.org/W2290528591","doi":"https://doi.org/10.1093/ofid/ofv133.608","title":"Randomized, Double-Blind, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia Suspected or Confirmed Caused by Gram-Positive Pathogens","display_name":"Randomized, Double-Blind, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia Suspected or Confirmed Caused by Gram-Positive Pathogens","publication_year":2015,"publication_date":"2015-01-01","ids":{"openalex":"https://openalex.org/W2290528591","doi":"https://doi.org/10.1093/ofid/ofv133.608","mag":"2290528591"},"language":"en","primary_location":{"id":"doi:10.1093/ofid/ofv133.608","doi":"https://doi.org/10.1093/ofid/ofv133.608","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofv133.608","pdf_url":null,"source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1093/ofid/ofv133.608","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016570350","display_name":"David B. Huang","orcid":"https://orcid.org/0000-0001-8228-7911","observed_orcids":["https://orcid.org/0000-0001-8228-7911","https://orcid.org/0000-0002-8342-3193"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Huang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101664224","display_name":"Mark A. Wilcox","orcid":"https://orcid.org/0000-0002-0686-8092","observed_orcids":["https://orcid.org/0000-0002-0686-8092"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Wilcox","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077693751","display_name":"Paul Hadv\u00e1ry","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul Hadvary","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5111659099","display_name":"Ralph G. Corey","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ralph Corey","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4053,"currency":"USD","value_usd":4053},"apc_paid":{"value":4053,"currency":"USD","value_usd":4053},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.19155963,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"2","issue":"suppl_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11681","display_name":"Nosocomial Infections in ICU","score":0.388700008392334,"subfield":{"id":"https://openalex.org/subfields/2706","display_name":"Critical Care and Intensive Care Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11681","display_name":"Nosocomial Infections in ICU","score":0.388700008392334,"subfield":{"id":"https://openalex.org/subfields/2706","display_name":"Critical Care and Intensive Care Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11036","display_name":"Antibiotics Pharmacokinetics and Efficacy","score":0.3163999915122986,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10195","display_name":"Antimicrobial Resistance in Staphylococcus","score":0.07370000332593918,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/iclaprim","display_name":"iclaprim","score":0.996999979019165},{"id":"https://openalex.org/keywords/vancomycin","display_name":"vancomycin","score":0.9900000095367432},{"id":"https://openalex.org/keywords/hospital-acquired-pneumonia","display_name":"nosocomial pneumonia","score":0.8830000162124634},{"id":"https://openalex.org/keywords/ventilator-associated-pneumonia","display_name":"ventilator-associated pneumonia","score":0.9639999866485596},{"id":"https://openalex.org/keywords/healthcare-associated-pneumonia","display_name":"healthcare-associated pneumonia","score":0.7720000147819519},{"id":"https://openalex.org/keywords/diaminopyrimidines","display_name":"diaminopyrimidines","score":0.7929999828338623},{"id":"https://openalex.org/keywords/dihydrofolate-reductase-inhibitors","display_name":"dihydrofolate reductase inhibitors","score":0.9549999833106995},{"id":"https://openalex.org/keywords/antibiotic-dosing-regimens","display_name":"antibiotic dosing regimens","score":0.8040000200271606},{"id":"https://openalex.org/keywords/clinical-cure-rate","display_name":"clinical cure rate","score":0.8289999961853027},{"id":"https://openalex.org/keywords/28-day-mortality","display_name":"28-day mortality","score":0.847000002861023},{"id":"https://openalex.org/keywords/staphylococcus-aureus","display_name":"Staphylococcus aureus","score":0.8519999980926514},{"id":"https://openalex.org/keywords/streptococcus-pneumoniae","display_name":"Streptococcus pneumoniae","score":0.9039999842643738},{"id":"https://openalex.org/keywords/staphylococcus-agalactiae","display_name":"Staphylococcus agalactiae","score":0.8629999756813049},{"id":"https://openalex.org/keywords/streptococcal-infection","display_name":"streptococcal infection","score":0.5630000233650208},{"id":"https://openalex.org/keywords/antibiotic-efficacy-and-safety","display_name":"antibiotic efficacy and safety","score":0.5270000100135803}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9446510076522827},{"id":"https://openalex.org/C2778980435","wikidata":"https://www.wikidata.org/wiki/Q424027","display_name":"Vancomycin","level":4,"score":0.6571850776672363},{"id":"https://openalex.org/C2777914695","wikidata":"https://www.wikidata.org/wiki/Q12192","display_name":"Pneumonia","level":2,"score":0.5959702730178833},{"id":"https://openalex.org/C2777184939","wikidata":"https://www.wikidata.org/wiki/Q7920253","display_name":"Ventilator-associated pneumonia","level":3,"score":0.5700705051422119},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.5262719392776489},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.469009131193161},{"id":"https://openalex.org/C73751289","wikidata":"https://www.wikidata.org/wiki/Q2985397","display_name":"Data monitoring committee","level":3,"score":0.45987385511398315},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.34072571992874146},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2150014340877533},{"id":"https://openalex.org/C2779489039","wikidata":"https://www.wikidata.org/wiki/Q188121","display_name":"Staphylococcus aureus","level":3,"score":0.13673701882362366},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C523546767","wikidata":"https://www.wikidata.org/wiki/Q10876","display_name":"Bacteria","level":2,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1093/ofid/ofv133.608","doi":"https://doi.org/10.1093/ofid/ofv133.608","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofv133.608","pdf_url":null,"source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1093/ofid/ofv133.608","doi":"https://doi.org/10.1093/ofid/ofv133.608","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofv133.608","pdf_url":null,"source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2741632646","https://openalex.org/W2752713307","https://openalex.org/W2789912955","https://openalex.org/W2799714015","https://openalex.org/W2804406807","https://openalex.org/W3010816592","https://openalex.org/W2778606863","https://openalex.org/W2896658653","https://openalex.org/W2158190550","https://openalex.org/W2782076686"],"abstract_inverted_index":{"Background.":[0],"Intravenous":[1],"iclaprim":[2],"(ICL),":[3],"a":[4,10,68,131,199,351],"new":[5,373],"generation":[6],"diaminopyrimidine":[7],"compound,":[8],"is":[9,385],"dihydrofolate":[11],"reductase":[12],"inhibitor":[13],"antibiotic":[14],"in":[15,48,205,210,224,255,298,328],"clinical":[16,28,132,347,383],"development.":[17],"The":[18,121,268,302],"primary":[19,122],"objective":[20],"of":[21,31,35,51,128,147,157,162,196,246,274,277,306,312,316,326,378],"the":[22,27,49,117,126,145,155,233,238,252,256,275,284,299,317,329],"study":[23],"was":[24,67,125,144,308],"to":[25,59,79,387],"compare":[26],"cure":[29,133,250,348],"rates":[30,229,270,349],"ICL":[32,80,84,176,180,234,285,290,307,344,368,389],"dosing":[33],"regimens":[34],"0.8":[36,81,177,257,286,330],"mg/kg":[37,41,82,86,178,182,258,261,287,292,331,335],"q12h":[38,47,92,288,332],"and":[39,96,104,112,167,172,184,213,219,244,264,281,289,296,324,338,350,407,415,420,425,432,437,442,449],"1.2":[40,85,181,260,291,334],"q8h":[42,262,293,336],"with":[43,53,241,310,357,363],"vancomycin":[44,89,185,239,265,300,339],"1":[45,90,225],"g":[46,91],"treatment":[50,102,278,340,377],"patients":[52,129,148,164,197,248,319,327,356],"nosocomial":[54,358,379],"pneumonia":[55],"suspected":[56],"or":[57,88],"confirmed":[58],"be":[60,370],"caused":[61],"by":[62,366],"Gram-positive":[63],"pathogens.":[64],"Methods.":[65],"This":[66],"double-blind,":[69],"randomized,":[70],"multicenter":[71],"Phase":[72],"2":[73],"study.":[74],"Patients":[75],"were":[76,97,165,191,230,279,361],"randomized":[77,166],"1:1:1":[78],"q12h,":[83,179,187,259],"q8h,":[87,183],"for":[93,232,237,283,376,390],"7-21":[94],"days,":[95],"evaluated":[98],"daily":[99],"during":[100],"their":[101],"course":[103],"at":[105,134,251],"EOT,":[106],"TOC":[107,118,135,253],"(7\u201314":[108,114],"days":[109,115,153,273],"post":[110],"treatment),":[111],"LFU":[113],"after":[116,154],"visit)":[119],"visits.":[120],"efficacy":[123],"endpoint":[124,143],"proportion":[127,146],"achieving":[130,249],"based":[136],"on":[137],"investigator":[138],"assessment.":[139],"A":[140,160,381],"key":[141],"secondary":[142],"who":[149,174],"died":[150],"within":[151,271],"28":[152,272],"start":[156,276],"treatment.":[158],"Results.":[159],"total":[161],"70":[163,318],"treated,":[168],"including":[169],"23,":[170],"24":[171],"23":[173],"received":[175],"1g":[186],"respectively.":[188,267,342],"Demographic":[189],"characteristics":[190],"comparable":[192,309,362],"across":[193],"treatments.":[194],"30%":[195],"had":[198],"baseline":[200],"pathogen":[201],"identified:":[202],"S.":[203,208,214],"aureus":[204],"15":[206],"patients,":[207,212],"pneumoniae":[209],"5":[211],"agalactiae,":[215],"\u03b2-hemolytic":[216,220],"Group":[217,221],"C,":[218],"F":[222],"streptococcus":[223],"patient":[226],"each.":[227],"Cure":[228],"higher":[231],"groups":[235],"than":[236],"group":[240],"73.9%,":[242],"62.5%,":[243],"52.2%":[245],"ITT":[247],"visit":[254],"ICL,":[263,333,337],"groups,":[266,294,341],"death":[269],"8.7%":[280],"12.5%":[282],"respectively,":[295],"21.7%":[297],"group.":[301],"adverse":[303],"event":[304],"profile":[305,354],"that":[311],"vancomycin.":[313,367],"Overall,":[314],"55":[315],"reported":[320],"TEAEs;":[321],"82.6%,":[322],"70.8%,":[323],"82.6%":[325],"Conclusion.":[343],"showed":[345],"high":[346],"good":[352],"safety":[353],"among":[355],"pneumonia,":[359],"which":[360],"those":[364],"achieved":[365],"could":[369],"an":[371],"important":[372],"therapeutic":[374],"option":[375],"pneumonia.":[380],"pivotal":[382],"trial":[384],"warranted":[386],"evaluate":[388],"this":[391],"indication.":[392],"Disclosures.":[393],"D.":[394],"Huang,":[395],"Motif":[396,402,456],"BioSciences:":[397,403,457],"Employee,":[398],"Salary;":[399],"M.":[400],"Wilcox,":[401],"Consultant,":[404,412,458],"Scientific":[405,413,426,433,443,450],"Advisor":[406,414],"Shareholder,":[408],"Consulting":[409,418,428,435,445,452,459],"fee.":[410,429,446],"Pfizer:":[411],"Speaker's":[416],"Bureau,":[417],"fee":[419,436,460],"Speaker":[421,438],"honorarium.":[422,439],"Durata:":[423],"Consultant":[424,431,441,448],"Advisor,":[427,434,444,451],"Cerexa:":[430],"Paratek:":[440],"Nabriva:":[447],"fee;":[453],"R.":[454],"Corey,":[455]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}